UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer

Breast cancer research and treatment, 2019-01, Vol.173 (1), p.135-143

2019

Volltextzugriff (PDF)

Spiny Keratoderma der Hand- und Fußflächen - einmal gesehen, nie wieder vergessen

Journal der Deutschen Dermatologischen Gesellschaft, 2017-09, Vol.15 (9), p.938

2017

Volltextzugriff (PDF)

Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9589-9589

2023

Volltextzugriff (PDF)

Radiosensibilisierung durch BRAF Inhibitoren

Journal der Deutschen Dermatologischen Gesellschaft, 2017-07, Vol.15 (7), p.703-708

2017

Volltextzugriff (PDF)

Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9528-9528

2023

Volltextzugriff (PDF)

Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?

Dermatology (Basel), 2015-01, Vol.230 (1), p.8-10

2015

Volltextzugriff (PDF)

Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9545-9545

2021

Volltextzugriff (PDF)

Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.9529-9529

2024

Volltextzugriff (PDF)

Nicht-bullöser neutrophiler Lupus erythematodes: Fallbericht einer seltenen Entität

Journal der Deutschen Dermatologischen Gesellschaft, 2014-06, Vol.12 (6), p.507-510

2014

Volltextzugriff (PDF)

Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS9589-TPS9589

2022

Volltextzugriff (PDF)

Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF V600 -mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING MELANOMA

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9526-9526

2022

Volltextzugriff (PDF)

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing

Breast cancer research and treatment, 2019-01, Vol.173 (1), p.135

2019

Volltextzugriff (PDF)

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Journal der Deutschen Dermatologischen Gesellschaft, 2019-09, Vol.17 (9), p.940-942

2019

Volltextzugriff (PDF)

Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA)

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14104-e14104

2019

Volltextzugriff (PDF)

Spiny keratoderma of the palms and soles – once seen, never forgotten

Journal der Deutschen Dermatologischen Gesellschaft, 2017-09, Vol.15 (9), p.939-941

2017

Volltextzugriff (PDF)

Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9570-9570

2022

Volltextzugriff (PDF)

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.104-104

2022

Volltextzugriff (PDF)

The GERMELATOX-A (Dermatologic Cooperative Oncology Group): Study attitude of German melanoma patients towards toxicity during adjuvant treatment

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e21597-e21597

2022

Volltextzugriff (PDF)

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.10011-10011

2020

Volltextzugriff (PDF)

Spiny Keratoderma der Hand‐ und Fußflächen – einmal gesehen, nie wieder vergessen

Journal der Deutschen Dermatologischen Gesellschaft, 2017-09, Vol.15 (9), p.938-940

2017

Volltextzugriff (PDF)

Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9531-9531

2021

Volltextzugriff (PDF)

Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERING MELANOMA

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9555-9555

2021

Volltextzugriff (PDF)

Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21513-e21513

2021

Volltextzugriff (PDF)

Overall survival benefit from tebentafusp in patients with best response of progressive disease

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9509-9509

2021

Volltextzugriff (PDF)

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9527-9527

2021

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(53)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(55)
Berichte
(3)

Sprache

Englisch
(55)
Deutsch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Dermatology
(7)
Humans
(5)
Female
(4)
Aged
(3)
Melanoma
(3)
Adjuvant Chemotherapy
(2)
Alopecia
(2)
Anthracyclines
(2)
Antineoplastic Agents - Adverse Effects
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Breast Cancer
(2)
Cancer Treatment
(2)
Chemotherapy
(2)
Diagnosis, Differential
(2)
Disease Progression
(2)
Indoles - Adverse Effects
(2)
Indoles - Therapeutic Use
(2)
Male
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(34)
Journal Der Deutschen Dermatologischen Gesellschaft
(16)
Breast Cancer Research And Treatment
(2)
Kompass Onkologie
(2)
Dermatology
(1)

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer

Spiny Keratoderma der Hand- und Fußflächen - einmal gesehen, nie wieder vergessen

Early ctDNA reduction may identify patients with stable disease and long OS on tebentafusp

Radiosensibilisierung durch BRAF Inhibitoren

Anti-PD1 plus BRAF/MEK inhibitors (triplet therapy) after failure of standard therapy in patients (pts) with advanced melanoma

Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?

Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy

Comparison of clinical outcomes of stable disease with confirmed tumor reduction and RECIST partial response for tebentafusp in metastatic uveal melanoma (mUM)

Nicht-bullöser neutrophiler Lupus erythematodes: Fallbericht einer seltenen Entität

Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma

Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAF V600 -mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERING MELANOMA

COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

Evaluation of radiotherapeutic and immune-modulatory response to whole brain radiotherapy or stereotactic radiosurgery in patients with brain metastases from malignant melanoma treated with or without ipilimumab (ELEKTRA)

Spiny keratoderma of the palms and soles – once seen, never forgotten

Multicenter real-world data of adjuvant treatment and disease outcome of patients with melanoma with high-risk of recurrence

Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM)

The GERMELATOX-A (Dermatologic Cooperative Oncology Group): Study attitude of German melanoma patients towards toxicity during adjuvant treatment

Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasized melanoma

Spiny Keratoderma der Hand‐ und Fußflächen – einmal gesehen, nie wieder vergessen

Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM)

Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAF V600 -mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERING MELANOMA

Characterization of liver function tests (LFTs) following tebentafusp (tebe) in previously treated (2L+) metastatic uveal melanoma (mUM) patients (pts)

Overall survival benefit from tebentafusp in patients with best response of progressive disease

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma

Suchergebnisse filtern